258 related articles for article (PubMed ID: 3173907)
1. Comparison of 99Tcm-labelled MDP and DMAD bone scanning agents in patients with advanced breast cancer.
Coleman RE; Meier CA; Rubens RD; Fogelman I
Nucl Med Commun; 1988 Jul; 9(7):481-5. PubMed ID: 3173907
[TBL] [Abstract][Full Text] [Related]
2. A clinical comparison of MDP and DMAD.
Rosenthall L; Stern J; Arzoumanian A
Clin Nucl Med; 1982 Sep; 7(9):403-6. PubMed ID: 6214358
[TBL] [Abstract][Full Text] [Related]
3. New diphosphonate compounds for skeletal imaging: comparison with methylene diphosphonate.
Subramanian G; McAfee JG; Thomas FD; Feld TA; Zapf-Longo C; Palladino E
Radiology; 1983 Dec; 149(3):823-8. PubMed ID: 6316414
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of a technetium-99m bone imaging agent based on the vicinal diphosphonate 1,2-diphosphonoethyleneglycol (DPEG).
Pauwels EK; Camps JA; Blom J; Hermans J; Kelly JD; Cumming SA; Blackburn GM; Rashid A
Nucl Med Commun; 1985 Nov; 6(11):739-45. PubMed ID: 3831848
[TBL] [Abstract][Full Text] [Related]
5. 99Tcm-MDP and 99Tcm-DPD in pathologic bone lesions. A visual and quantitative comparison.
Lantto T; Vorne M; Mokka R; Vähätalo S
Acta Radiol; 1987; 28(5):631-3. PubMed ID: 2960361
[TBL] [Abstract][Full Text] [Related]
6. A comparison of bone imaging with Tc-99m DPD and Tc-99m MDP: concise communication.
Buell U; Kleinhans E; Zorn-Bopp E; Reuschel W; Muenzing W; Moser EA; Seiderer M
J Nucl Med; 1982 Mar; 23(3):214-7. PubMed ID: 6460854
[TBL] [Abstract][Full Text] [Related]
7. Technetium-99m complexes of dimethylaminomethylene diphosphonate (DMAD)--II. Biological distributions of 99mTc-DMAD components isolated by anion exchange HPLC.
Holland ME; Bugaj J; Heineman WR; Deutsch E
Int J Rad Appl Instrum B; 1989; 16(3):313-7. PubMed ID: 2497091
[TBL] [Abstract][Full Text] [Related]
8. Improved lesion detection with dimethyl-amino-diphosphonate: a report of two cases.
Smith ML; Martin W; McKillop JH; Fogelman I
Eur J Nucl Med; 1984; 9(11):519-20. PubMed ID: 6240401
[TBL] [Abstract][Full Text] [Related]
9. Diphosphonate bone scanning agents--current concepts.
Fogelman I
Eur J Nucl Med; 1982; 7(11):506-9. PubMed ID: 6217074
[TBL] [Abstract][Full Text] [Related]
10. Technetium-99m-labeled methylene diphosphonate and hydroxyethylidine diphosphonate--biologic and clinical comparison: concise communication.
Rudd TG; Allen DR; Smith FD
J Nucl Med; 1979 Aug; 20(8):821-6. PubMed ID: 120422
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of the bone marrow imaging agent 99Tcm-phytate in the detection of bone metastases.
Chang CP; Liu RS; Yu SM; Wynchank S; Chu LS; Shiau HY; Cheng TC
Nucl Med Commun; 1996 Dec; 17(12):1030-4. PubMed ID: 9004298
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of metastatic bone disease with pentavalent 99Tc(m)-dimercaptosuccinic acid: a comparison with whole-body scanning and 4/24 hour quantitation of vertebral lesions.
Sahin M; Basoglu T; Bernay I; Yapici O; Canbaz F; Yalin T
Nucl Med Commun; 2000 Mar; 21(3):251-8. PubMed ID: 10823327
[TBL] [Abstract][Full Text] [Related]
13. Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results.
Morris PG; Poznak CV; Modi S; Mak AF; Patil S; Larson S; Hudis CA; Divgi C; Grewal RK
Clin Breast Cancer; 2010 Feb; 10(1):33-9. PubMed ID: 20133256
[TBL] [Abstract][Full Text] [Related]
14. Adverse allergic reaction to technetium-99m methylene diphosphonate.
Spicer JA; Preston DF; Stephens RL
J Nucl Med; 1985 Apr; 26(4):373-4. PubMed ID: 2984362
[TBL] [Abstract][Full Text] [Related]
15. Clinical comparison of bone scintigraphy with 99Tcm-DPD, 99Tcm-HDP and 99Tcm-MDP.
Bergqvist L; Brismar J; Cederquist E; Darte L; Naversten Y; Palmer J
Acta Radiol Diagn (Stockh); 1984; 25(3):217-23. PubMed ID: 6236672
[TBL] [Abstract][Full Text] [Related]
16. A clinical comparison of Tc-99m HEDP and Tc-99m MDP in the detection of bone metastases: concise communication.
Fogelman I; Citrin DL; McKillop JH; Turner JG; Bessent RG; Greig WR
J Nucl Med; 1979 Feb; 20(2):98-101. PubMed ID: 430202
[TBL] [Abstract][Full Text] [Related]
17. Enhanced uptake of 99Tcm-MDP in skeletal metastases from prostate cancer following initiation of hormone treatment: potential for increasing delivery of therapeutic agents.
Bushnell DL; Madsen M; Kahn D; Nathan M; Williams RD
Nucl Med Commun; 1999 Oct; 20(10):875-81. PubMed ID: 10528290
[TBL] [Abstract][Full Text] [Related]
18. Technetium-99m-MIBI uptake in benign and malignant bone lesions: a comparative study with technetium-99m-MDP.
Caner B; Kitapçl M; Unlü M; Erbengi G; Calikoğlu T; Göğüş T; Bekdik C
J Nucl Med; 1992 Mar; 33(3):319-24. PubMed ID: 1531501
[TBL] [Abstract][Full Text] [Related]
19. Technetium-99m MDP vs technetium-99m dicarboxypropane diphosphonate. A clinical comparison in various pathologic conditions.
Godart G; Durez M; Bevilacqua M; Abramovici J; Robience Y
Clin Nucl Med; 1986 Feb; 11(2):92-7. PubMed ID: 3769350
[TBL] [Abstract][Full Text] [Related]
20. A comparison between the diagnostic efficacy of 99mTc-MDP, 99mTc-DPD and 99mTc-HDP for the detection of bone metastases.
Pauwels EK; Blom J; Camps JA; Hermans J; Rijke AM
Eur J Nucl Med; 1983; 8(3):118-22. PubMed ID: 6220908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
